Eravacycline

Everest Medicines Announces Commercial Launch and First Prescription for XERAVA® in China

Retrieved on: 
Thursday, July 27, 2023
Vaccine, Neutropenia, VRE, Fungal infection, Eravacycline, Infection, Fever, New Drug Application, MRSA, Gram-negative bacteria, NDA, Urinary tract infection, First Affiliated Hospital of Xinjiang Medical University, Hematopoietic stem cell transplantation, Soochow University, Incidence, MDR, Radiation, HKEX, Patient, National Medical Products Administration, Huashan Hospital, Fudan University, IgA nephropathy, CRE, NMPA, Pharmaceutical industry, Mount Everest

SHANGHAI, July 26, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today XERAVA® (eravacycline) has been successfully launched in China with its first prescription issued at Huashan Hospital affiliated to Fudan University. The commercialization of XERAVA® in China marks Everest's transformation into a commercial-stage innovative biopharmaceutical company.

Key Points: 
  • "The commercialization of XERAVA® in China is a significant milestone for Everest as a company, as this marks the beginning of Everest as a commercial-stage biopharma company.
  • I want to thank everyone involved in bringing XERAVA® to a successful launch," said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines.
  • "After the commercial launch, we will accelerate patient access to XERAVA® with a lean commercial team, following a highly efficient commercial strategy.
  • The launch of eravacycline in China will help doctors tackle the challenges of clinical drug resistance."

Everest Medicines Announces New Strategic Plans, Reinforcing Transformation into a Fully Integrated Biopharmaceutical Company

Retrieved on: 
Tuesday, January 3, 2023
IgA nephropathy, Patient, Immunoglobulin A, Social conditions in Honduras, Partnership, RNA transfection, Growth, CMC, COVID-19, Mount Everest, HKEX, Eravacycline, Ulcerative colitis, News, Degenerative disease, Prevalence, Infection, NDA, Cancer, Vaccine, Emergency Use Authorization, Kidney, Pharmaceutical industry

SHANGHAI, Jan. 3, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its strategic plans for the next two years and beyond as the Company progresses to becoming a fully-integrated biopharmaceutical company with expertise and capabilities across the full biotechnology value chain, including proven self-discovery and in-licensing, clinical development, and established manufacturing and commercialization . The Company's renal disease and mRNA platform portfolios, both of which comprise multiple promising early- and late-stage therapeutic candidates, will be Everest's core areas of focus.

Key Points: 
  • The Company's renal disease and mRNA platform portfolios, both of which comprise multiple promising early- and late-stage therapeutic candidates, will be Everest's core areas of focus.
  • The potential approval and launch of Nefecon, the Company's lead renal portfolio product candidate, is expected in China in the second half of 2023.
  • Everest Medicines is a biopharmaceutical company focused on developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets.
  • Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules, many of which are in late-stage clinical development.

EQS-News: PAION AG enters partnership with Viatris and expands sales activities in Europe

Retrieved on: 
Sunday, November 27, 2022
Growth, Frankfurt Stock Exchange, EMA, Partnership, Physician, Patient, Angiotensin, Critical care, ISIN, Paion, Multiplicity of infection, Hypotension, Septic, Distributive shock, Medis, Security (finance), Pharmaceutical industry, Viatris, Eravacycline, Anesthesia, Remimazolam, EU

Under the terms of the collaboration agreement, on the one hand, PAION will receive a upfront payment.

Key Points: 
  • Under the terms of the collaboration agreement, on the one hand, PAION will receive a upfront payment.
  • In addition, Viatris will purchase supply of the products from PAION and also share with them the profits from product sales.
  • Commenting on the sales activities, Dr. Jim Phillips, CEO of PAION AG, said: "We are very pleased to have entered into a long-term partnership with leading global healthcare company Viatris to provide access to medicines for patients in Europe.
  • This is an important milestone for PAION to drive forward its sales activities in Europe in a targeted manner.

EQS-News: PAION AG reports financial results for the first nine months of 2022

Retrieved on: 
Sunday, November 27, 2022
Marketing, European Medicines Agency, Intangibles, EBITDA, Degenerative disease, Annual, Eravacycline, European Investment Bank, Frankfurt Stock Exchange, International Financial Reporting Standards, Health care, EMA, Keur Simbara, USD, EIB, Critical care, Annual report, Remimazolam, ISIN, Research, European Commission, Federal Joint Committee (Germany), Standard of care, Patent, International, Sale, MHRA, ERP, II, Angiotensin, Medication, EUR, Acquisition, EU, Medis, Health insurance, Pharmaceutical industry, Real estate, Airline, Film, Bank

In April 2022, PAION was informed that the Federal Joint Committee (G-BA) had approved PAION's application for eravacycline (XERAVA) as a reserve antibiotic.

Key Points: 
  • In April 2022, PAION was informed that the Federal Joint Committee (G-BA) had approved PAION's application for eravacycline (XERAVA) as a reserve antibiotic.
  • PAION is now exempt from providing a full benefit dossier and is only required to provide an abbreviated dossier by 1st August 2022.
  • Revenues increased to EUR 25.6 million in the first nine months of 2022 (same period last year: EUR 5.5 million).
  • Based on the results for the first nine months of 2022, PAION raises the outlook for the full year 2022 announced with the Annual Report 2021.

DGAP-News: PAION AG reports financial results for the first half-year 2022

Retrieved on: 
Wednesday, August 31, 2022
European Medicines Agency, Health care, ISIN, EMA, Research, CEO, EU, II, Degenerative disease, Angiotensin, Critical care, USD, Sale, IFRS, Standard of care, EDT, Federal Joint Committee (Germany), Remimazolam, API, EIB, EUR, Frankfurt Stock Exchange, Medication, Patent, Eravacycline, Conference, International, MHRA, CEST, Annual report, European Commission, Annual, Conference call, Marketing, International Financial Reporting Standards, Online gambling, Renewable energy, Pharmaceutical industry, Medical device

PAION is now exempt from providing a full benefit dossier and is only required to provide an abbreviated dossier by 1st August 2022.

Key Points: 
  • PAION is now exempt from providing a full benefit dossier and is only required to provide an abbreviated dossier by 1st August 2022.
  • The sale of angiotensin II (GIAPREZA) was expanded from Germany to the Netherlands and Austria in early 2022.
  • In China, PAION entered into a patent assignment agreement with Humanwell at the beginning of 2022.
  • EUR 16 million were received in the first quarter of 2022, and the remaining EUR 4.5 million have been paid in June 2022.

Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava™ in Taiwan

Retrieved on: 
Thursday, August 11, 2022
Social conditions in Honduras, Gastrointestinal tract, Cholecystitis, Aerobic organism, NDA, Peritonitis, MDR, Daptomycin, Technology, Multiplicity of infection, Philippe Ciais, Cancer, Life, Critical care, Marketing, Patient, Review, Bronchopneumonia, Stomach, Appendicitis, Company, Infection, HKEX, Partnership, Tetracycline, Doctor of Philosophy, Degenerative disease, Perforation, News, TTY, Gram-positive bacteria, Solution, CMC, Diverticulitis, Medicine, Food, Terminology, Pharmaceutical industry, Vaccine, Colistin, Eravacycline, Mount Everest, MD

SHANGHAI, Aug. 10, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced today that the Taiwan Food and Drug Administration (TFDA) has accepted the submission of a New Drug Application (NDA) for Xerava™ (eravacycline) for the treatment of complicated intra-abdominal infections (cIAI).

Key Points: 
  • In addition, the Company has entered into an exclusive partnership agreement with TTY Biopharm (TTY) for commercialization of Xerava in Taiwan.
  • It is not only being one of the top pharmaceutical companies in Taiwan, but also focuses on international marketing.
  • Under the partnership, which includes a 10-year term upon the launch of Xerava in Taiwan with possibility of extension, TTY will be responsible for all commercialization of the product in Taiwan.
  • Everest Medicines has built a portfolio of elevenpotentially global first-in-class or best-in-class molecules, many of which are in late stage clinical development.

DGAP-News: PAION LAUNCHES ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN ADULTS IN GERMANY

Retrieved on: 
Monday, August 1, 2022
IDSA, Philippe Ciais, Anesthesia, Infection, EU, Infectious Diseases Society of America, Ertapenem, Abscess, Distributive shock, ISIN, Remimazolam, Intra-abdominal infection, Angiotensin, Tetracycline, PA8, Royal commission, Eravacycline, Sepsis, Federal Joint Committee (Germany), Septic, Hypotension, Aachen, Product, Abdominal cavity, European Commission, European Medicines Agency, Frankfurt Stock Exchange, Patient, Health, Peritonitis, Multiplicity of infection, Meropenem, ICU, Critical care, Dietary supplement, Pharmaceutical industry, European

In April 2022, the Federal Joint Committee (G-BA) voted in favour of PAIONs application for eravacycline as a reserve antibiotic.

Key Points: 
  • In April 2022, the Federal Joint Committee (G-BA) voted in favour of PAIONs application for eravacycline as a reserve antibiotic.
  • Eravacycline is approved by the European Commission and the UK Medicines Agency for the treatment of complicated intra-abdominal infections (cIAI) in adults.
  • Eravacycline is an important new treatment option for patients suffering from serious intra-abdominal infections.
  • Eravacycline is an antibiotic used to treat complicated intra-abdominal infections (cIAI) in adults.

SOM Biotech announces poster presentation on the repurposing of Eravacycline for the treatment of SARS-CoV-2

Retrieved on: 
Thursday, October 22, 2020
Sarbecovirus, Respiratory diseases, 3C-like protease, Eravacycline, Animal diseases, Infectious diseases, Severe acute respiratory syndrome, Coronavirus disease

The poster is entitled "Repurposing of Eravacycline for the Treatment of SARS-CoV-2 Infections" and outlines pre-clinical data demonstrating that Eravacycline is a potent inhibitor of the SARS-CoV-2 3CL protease.

Key Points: 
  • The poster is entitled "Repurposing of Eravacycline for the Treatment of SARS-CoV-2 Infections" and outlines pre-clinical data demonstrating that Eravacycline is a potent inhibitor of the SARS-CoV-2 3CL protease.
  • Covalent docking calculations demonstrated that Eravacycline establishes a covalent bond with Cys145 in the catalytic domain of the SARS-CoV-2 3CL protease.
  • "We are pleased to share our in vitro findings on Eravacycline for the treatment of SARS-CoV-2 and to target the hospitalized patients by the virus.
  • A Phase 2 clinical trial is planned to prove the efficacy of Eravacycline in hospitalized COVID-19 patients", says Raul Insa, CEO of SOM Biotech.

SOM Biotech announces poster presentation on the repurposing of Eravacycline for the treatment of SARS-CoV-2

Retrieved on: 
Thursday, October 22, 2020
Sarbecovirus, Respiratory diseases, 3C-like protease, Eravacycline, Animal diseases, Infectious diseases, Severe acute respiratory syndrome, Coronavirus disease

The poster is entitled "Repurposing of Eravacycline for the Treatment of SARS-CoV-2 Infections" and outlines pre-clinical data demonstrating that Eravacycline is a potent inhibitor of the SARS-CoV-2 3CL protease.

Key Points: 
  • The poster is entitled "Repurposing of Eravacycline for the Treatment of SARS-CoV-2 Infections" and outlines pre-clinical data demonstrating that Eravacycline is a potent inhibitor of the SARS-CoV-2 3CL protease.
  • Covalent docking calculations demonstrated that Eravacycline establishes a covalent bond with Cys145 in the catalytic domain of the SARS-CoV-2 3CL protease.
  • "We are pleased to share our in vitro findings on Eravacycline for the treatment of SARS-CoV-2 and to target the hospitalized patients by the virus.
  • A Phase 2 clinical trial is planned to prove the efficacy of Eravacycline in hospitalized COVID-19 patients", says Raul Insa, CEO of SOM Biotech.

Everest Medicines Completes Enrollment of Phase 3 Clinical Trial of Xerava™ (eravacycline) for the Treatment of Complicated Intra-Abdominal Infections in China

Retrieved on: 
Friday, August 28, 2020
Health, Chemical compounds, Drug discovery, Pharmaceutical industry, Eravacycline, Pyrrolidines, Clinical research, RTT, Clinical trial, Ceftolozane/tazobactam

Top-line results from this China trial are expected in the fourth quarter of 2020 and plan to support Everest Medicines New Drug Application filing in China.

Key Points: 
  • Top-line results from this China trial are expected in the fourth quarter of 2020 and plan to support Everest Medicines New Drug Application filing in China.
  • Xerava represents an important potential new treatment option for the management of complicated infections, especially among drug resistant pathogens.
  • Xerava is currently approved for the treatment of complicated intra-abdominal infections (cIAI) in the US and EU.
  • The Company is conducting a Phase 3 clinical trial in China for cIAI to support regulatory approval to launch in China.